PMID: 2108850Apr 1, 1990Paper

Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy

Chest
D R Hirsch, S Z Goldhaber

Abstract

Widespread use of thrombolytic agents in a variety of settings has highlighted the need for measures of safety and efficacy. Previously used laboratory parameters, such as decreasing levels of fibrinogen and increasing levels of fibrin(ogen) degradation products (FDPs), have failed to correlate consistently with hemorrhagic events and have not yet been useful in predicting patients at risk for bleeding. Although the bleeding time (BT) has been considered primarily to reflect platelet function, it also reflects the interaction of platelets with vessel wall and coagulation pathways. Recently, the BT has been considered as a potential predictor of clinical bleeding during thrombolysis. The BT, as a measure of in vivo hemostatic competence, may be particularly well-suited for this application. Serial BTs during thrombolytic therapy may provide valuable information regarding safety and efficacy, but further studies are needed to confirm preliminary findings.

References

Jan 1, 1990·American Heart Journal·D R Hirsch, S Z Goldhaber
Jun 1, 1987·The Journal of Clinical Investigation·J Loscalzo, D E Vaughan
Jun 1, 1988·Journal of the American College of Cardiology·D E VaughanJ Loscalzo
Jul 1, 1973·The Journal of Clinical Investigation·S NiewiarowskiP Gillies
Jul 27, 1972·The New England Journal of Medicine·L A Harker, S J Slichter
Aug 1, 1984·The American Journal of Medicine·S E Lind

❮ Previous
Next ❯

Citations

Dec 30, 1998·Irish Journal of Medical Science·S M Lavelle, M MacIomhair

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.